Tanas M R, Ma S, Jadaan F O, Ng C K Y, Weigelt B, Reis-Filho J S, Rubin B P
Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Robert J. Tomsich Pathology Institute, Lerner Research Institute, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Oncogene. 2016 Feb 18;35(7):929-38. doi: 10.1038/onc.2015.148. Epub 2015 May 11.
The WWTR1 (protein is known as TAZ)-CAMTA1 (WC) fusion gene defines epithelioid hemangioendothelioma, a malignant vascular cancer. TAZ (transcriptional coactivator with PDZ binding motif) is a transcriptional coactivator and end effector of the Hippo tumor suppressor pathway. It is inhibited by phosphorylation by the Hippo kinases LATS1 and LATS2. Such phosphorylation causes cytoplasmic localization, 14-3-3 protein binding and the phorphorylation of a terminal phosphodegron promotes ubiquitin-dependent degradation (the phosphorylation of the different motifs has several effects). CAMTA1 is a putative tumor suppressive transcription factor. Here we demonstrate that TAZ-CAMTA1 (TC) fusion results in its nuclear localization and constitutive activation. Consequently, cells expressing TC display a TAZ-like transcriptional program that causes resistance to anoikis and oncogenic transformation. Our findings elucidate the mechanistic basis of TC oncogenic properties, highlight that TC is an important model to understand how the Hippo pathway can be inhibited in cancer, and provide approaches for targeting this chimeric protein.
WWTR1(蛋白质名为TAZ)-CAMTA1(WC)融合基因定义了上皮样血管内皮瘤,一种恶性血管癌。TAZ(具有PDZ结合基序的转录共激活因子)是Hippo肿瘤抑制途径的转录共激活因子和终末效应器。它被Hippo激酶LATS1和LATS2磷酸化抑制。这种磷酸化导致细胞质定位、14-3-3蛋白结合,并且末端磷酸降解基序的磷酸化促进泛素依赖性降解(不同基序的磷酸化有多种效应)。CAMTA1是一种假定的肿瘤抑制转录因子。在此我们证明TAZ-CAMTA1(TC)融合导致其核定位和组成性激活。因此,表达TC的细胞表现出类似TAZ的转录程序,导致对失巢凋亡和致癌转化产生抗性。我们的发现阐明了TC致癌特性的机制基础,强调TC是理解Hippo途径在癌症中如何被抑制的重要模型,并提供了靶向这种嵌合蛋白的方法。